RenovoRx's TAMP Platform Shows Promise in Locally Advanced Pancreatic Cancer
Event summary
- RenovoRx published a peer-reviewed case series in Case Reports in Oncology highlighting the TAMP™ Platform's potential to improve chemotherapeutic delivery for locally advanced pancreatic cancer.
- The study involved two patients with locally advanced pancreatic cancer who demonstrated tumor treatment response with reductions in CA 19-9 and favorable changes on imaging.
- Hackensack Meridian Health Jersey Shore University Medical Center has been using the TAMP Platform with the RenovoCath device in its oncology program for over a year.
- RenovoRx generated approximately $1.1 million in RenovoCath sales in 2025 and $909,000 in the second quarter of 2026.
- The company expects topline data readout from the Phase III TIGeR-PaC trial in the second half of 2027.
The big picture
RenovoRx's peer-reviewed publication underscores the potential of its TAMP™ Platform to enhance targeted chemotherapy delivery for locally advanced pancreatic cancer, a notoriously difficult-to-treat condition. The company's focus on expanding the use of RenovoCath in high-volume cancer centers aligns with broader industry trends toward precision oncology. With the Phase III TIGeR-PaC trial nearing completion, the next critical phase will be translating clinical data into commercial success and regulatory approval.
What we're watching
- Clinical Validation
- How the peer-reviewed publication will influence the adoption of the TAMP™ Platform in clinical settings.
- Commercial Expansion
- Whether RenovoRx can sustain its revenue growth by expanding the number of medical institutions using RenovoCath.
- Regulatory Milestones
- The pace at which the Phase III TIGeR-PaC trial results will impact the regulatory approval process for the IAG combination product.
Related topics
